Gavi signed agreement with Clover Biopharmaceuticals for supply to COVAX
On Jun. 30, 2021, Gavi, the Vaccine Alliance, announced that it had signed an advance purchase agreement with…
-
-
Biotechnology | COVID-19 | Diagnostics | NIH
NIH-funded screening study builds case for frequent COVID-19 antigen testing
On Jun. 30, 2021, the National Institutes of Health (NIH) announced a highly anticipated study that compared rapid…
-
XPhyto supplied 10 test centers in Berlin with 25-minute COVID-19 PCR test
On Jun. 30, 2021, XPhyto announces that it had signed a master supply agreement with Beovita GmbH &…
-
Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
-
Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…
-
Adjuvant developed with NIH funding enhanced efficacy of India’s COVID-19 vaccine
On Jun. 29, 2021, the National Institutes of Health announced that an adjuvant developed with its funding had…
-
Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…
-
India approves Moderna’s Covid-19 vaccine for emergency use
On Jun. 29, 2021, India announced it had authorized the emergency use of Moderna’s Covid-19 vaccine as it…
-
Altimmune announced update on AdCOVID phase 1 clinical trial
On Jun. 29, 2021, Altimmune provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19….
-
VBI Vaccines announced initial positive phase 1 data for its eVLP vaccine candidate against COVID-19
On Jun. 29, 2021, VBI Vaccines announced positive Phase 1 data from its Phase 1/2 trial of the…
-
First trial participants vaccinated with Oxford COVID-19 variant vaccine
On Jun. 28, 2021, the University of Oxford in partnership with AstraZeneca began vaccinations for a new phase…
-
Mixed Oxford/Pfizer vaccine schedules generated robust immune response against COVID-19
On Jun. 28, 2021, researchers running the University of Oxford-led Com-COV study reported that alternating doses of the…
-
Meridian resubmitted application to FDA for Emergency Use Authorization for Revogene SARS-CoV-2 molecular assay
On Jun. 28, 2021, Meridian Bioscience announced that it had re-submitted its application for Emergency Use Authorization (EUA)…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Genomics | Life Science History | Medicine | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 PPE distribution
Cast of Characters: Jay Inslee, Governor, Washington | Gavin Newsom, Governor, California | Doug Ducey, Governor, Arizona |…
-
Roche’s Actemra/RoActemra received FDA EUA for treatment of COVID-19 in hospitalised adults and children
On Jun. 25, 2021, Roche announced that the Food and Drug Administration (FDA) had issued an Emergency Use…
-
Oxford researchers identified levels of antibody protection required to prevent symptomatic COVID-19
On Jun. 25, 2021, researchers from the University of Oxford released their findings about the so-called ”correlates of…
-
NIH began sudy of COVID-19 vaccination during pregnancy and postpartum
On Jun. 23, 2021, the National Institutes of Health (NIH) announced that an observational study had begun to…
-
NIH study suggested COVID-19 prevalence far exceeded early pandemic cases
On Jun. 22, 2021, National Institutes of Health researchers reported that the prevalence of COVID-19 in the U.S….
-
European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…
-
BioReference Laboratories announces first COVID-19 testing program for cruise industry
On Jun. 22, 2021, BioReference Laboratories, an OPKO Health company, announced a COVID-19 testing program for U.S. based…
-
Gilead’s Veklury (Remdesivir) associated with reduction in mortality rate in hospitalized patients with COVID-19
On Jun. 21, 2021, Gilead Sciences announced positive data from three retrospective studies of the real-world treatment of…
-
Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients
On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…
-
Relief Therapeutics reported that NRx Pharma announced additional results from Aviptadil expanded access protocol for patients with COVID-19
On Jun. 16, 2021, RELIEF THERAPEUTICS reported that its collaboration partner, NRx Pharmaceuticals (NRx) had announced additional results…
-
RECOVERY trial found Regeneron’s monoclonal antibody combination reduced deaths for hospitalised COVID-19 patients
On Jun. 16, 2021, the University of Oxford announced the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrated…
-
U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
REGEN-COV phase 3 RECOVERY trial met primary outcome, improving survival in Hospitalized COVID-19 patients
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Data published in NEJM showed Pfizer’s Tofacitinib met primary endpoint in Brazilian study in patients with COVID-19 pneumonia
On Jun. 16, 2021, Pfizer and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced…
-
Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…
-
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
-
Cocrystal’s COVID-19 antiviral CDI-45205 shown to be active against SARS-CoV-2 and prominent SARS-CoV-2 variants
On Jun. 14, 2021, Cocrystal Pharma announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active…
